SCHEMBL6948244

SCHEMBL6948244

C[C@@H](NC(=O)c1ccccc1)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PREP P48147 1/20 0.43
FAP Q12884 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
MGLL Q99685 1/20 0.41
HPGD P15428 2/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.40
ACE P12821 1/20 0.40
CA2 P00918 2/20 0.40
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29091690 0.83 LMNA (0.46) CYP1A2CYP2C9SMN1; SMN2KDM4ETDP1
SCHEMBL21848509 0.83 LMNA (0.46) CYP1A2CYP2C9SMN1; SMN2KDM4ETDP1
SCHEMBL10335429 0.83 CTSL (0.51)
SCHEMBL3497149 0.81 MGLL (0.31) MGLL
SCHEMBL8644559 0.81 MGLL (0.31) MGLL
SCHEMBL8867086 0.81 MGLL (0.31) MGLL
SCHEMBL16865569 0.79 CTSL (0.41) ALDH1A1MGLLHPGDLMNAACE
SCHEMBL7202631 0.79 CTSL (0.58) GAAALDH1A1RAB9ALMNAACE
SCHEMBL14366653 0.79 CTSK (0.50) PREPCYP1A2CYP2D6CYP2C9RAB9A
SCHEMBL10345811 0.79 CTSK (0.50) PREPCYP1A2CYP2D6CYP2C9RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192128-A4 THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS MERCK & CO INC (US) 2003-07-02 EP disclosed
EP-1192128-A1 THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS Merck & Co., Inc. (US) 2002-04-03 EP disclosed
US-20020019543-A1 Thiol derivative, metallo-beta-lactamase inhibitors BALKOVEC JAMES M (US) 2002-02-14 US disclosed
WO-2000076962-A1 THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS MERCK & CO., INC. (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019543-A1 Thiol derivative, metallo-beta-lactamase inhibitors CBR1, LBR, CBR3 PREP 1851/4885FAP 3665/4885CYP1A2 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.